Comparative Pharmacology
Head-to-head clinical analysis: E E S versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus WYAMYCIN E.
E.E.S. vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic